European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 GuidelinesJ. Alfred Witjes, Antoine G. van der Heijden, Harman Max Bruins et al.|European Urology|2023Cited by 618
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2025 GuidelinesAntoine G. van der Heijden, Michael Rink, Matthew I. Milowsky et al.|European Urology|2025Cited by 159
FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment?†Bas W.G. van Rhijn, Tahlita C.M. Zuiverloon, Laura S. Mertens et al.|European Urology|2020Cited by 89
Oncological Outcomes in Bacillus Calmette-Guérin–naïve High-risk Non–muscle-invasive Bladder Cancer Patients: A Systematic Review on Current Treatment Strategies and Future PerspectivesMattia Longoni, Marco Moschini, Pietro Scilipoti et al.|European Urology Oncology|2025Cited by 43
Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patientsLaura S. Mertens, Bas W.G. van Rhijn, Francesco Claps et al.|Urologic Oncology Seminars and Original Investigations|2021Cited by 39